Comparison of the efficacy between intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in stage II nasopharyngeal carcinoma

被引:12
作者
Pan, Xin-Bin [1 ]
Chen, Kai-Hua [1 ]
Huang, Shi-Ting [1 ]
Jiang, Yan-Ming [1 ]
Ma, Jia-Lin [1 ]
Liang, Zhong-Guo [1 ]
Qu, Song [1 ]
Li, Ling [1 ]
Chen, Long [1 ]
Zhu, Xiao-Dong [1 ]
机构
[1] Guangxi Med Univ, Canc Hosp, Dept Radiat Oncol, Nanning, Guangxi, Peoples R China
关键词
nasopharyngeal carcinoma; intensity-modulated radiotherapy; two-dimensional conventional radiotherapy; RADIATION-THERAPY; HEAD; METAANALYSIS; IMRT;
D O I
10.18632/oncotarget.17481
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We compared treatment outcomes in patients with stage II nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy (IMRT) or two-dimensional conventional radiotherapy (2D-CRT). Stage II (2010 UICC/AJCC staging system) NPC patients treated with IMRT (n = 178) or 2D-CRT (n = 73) between January 2007 and December 2014 were retrospectively analyzed. Patients were matched using the propensity score-matching method. The primary endpoint was overall survival (OS). Secondary endpoints were local relapse-free survival (LRFS), regional relapse-free survival (RRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS). Acute and late toxicity reactions to IMRT and 2D-CRT were also compared. In an unmatched cohort of 251 patients, no significant survival differences were found between those receiving IMRT and those receiving 2D-CRT (5-year OS, 95.67% vs 94.44%, P = 0.0556; LRFS, 97.34% vs 98.59%, P = 0.6656; RRFS, 99.26% vs 100%, P = 0.6785; DMFS, 96.5% vs 98.63%, P = 0.7910; DFS, 92.2% vs 97.24%, P = 0.8719). In the propensity-matched cohort of 146 patients, 5-year OS (97.06% vs 94.44%, P = 0.1325), LRFS (96.75% vs 98.59%, P = 0.8869), RRFS (100% vs 100%, P = 1.0000), DMFS (98.63% vs 98.63%, P = 0.4225), and DFS (95.37% vs 97.24%, P = 0.5634) were similar between patients treated with IMRT or 2D-CRT. However, IMRT correlated with fewer acute and late toxicity reactions. Thus although IMRT provides no survival advantage, it has a lower incidence of toxicity than 2D-CRT in stage II NPC patients.
引用
收藏
页码:78096 / 78104
页数:9
相关论文
共 50 条
  • [21] Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma
    You, Rui
    Sun, Rui
    Hua, Yi-Jun
    Li, Chao-Feng
    Li, Ji-Bin
    Zou, Xiong
    Yang, Qi
    Liu, You-Ping
    Zhang, Yi-Nuan
    Yu, Tao
    Cao, Jing-Yu
    Zhang, Meng-Xia
    Jiang, Rou
    Mo, Hao-Yuan
    Guo, Ling
    Cao, Ka-Jia
    Lin, Ai-Hua
    Qian, Chao-Nan
    Sun, Ying
    Ma, Jun
    Chen, Ming-Yuan
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (06) : 1265 - 1276
  • [22] Sonographic Appearance of Thyroid Glands in Patients Treated with Intensity-Modulated Radiotherapy or Conventional Radiotherapy for Nasopharyngeal Carcinoma
    Cheng, Sammy C. H.
    Wu, Vincent W. C.
    Kwong, Dora L. W.
    Lui, C. Y.
    Cheng, Ashley C. K.
    Kot, Brian C. W.
    Ying, Michael T. C.
    [J]. JOURNAL OF CLINICAL ULTRASOUND, 2015, 43 (04) : 210 - 223
  • [23] Reirradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy
    Chua, DTT
    Sham, JST
    Leung, LHT
    Au, GKH
    [J]. RADIOTHERAPY AND ONCOLOGY, 2005, 77 (03) : 290 - 294
  • [24] Management of Chemotherapy for Stage II Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era: A Review
    Wu, Peng
    Zhao, Yumei
    Xiang, Li
    Yang, Linglin
    [J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 957 - 963
  • [25] HELICAL TOMOTHERAPY OF NASOPHARYNGEAL CARCINOMA-ANY ADVANTAGES OVER CONVENTIONAL INTENSITY-MODULATED RADIOTHERAPY?
    Wu, W. C. Vincent
    Mui, Wing-lun A.
    Fung, Wing-ki W.
    [J]. MEDICAL DOSIMETRY, 2010, 35 (02) : 122 - 127
  • [26] Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma
    Orlandi, Ester
    Tomatis, Stefano
    Potepan, Paolo
    Bossi, Paolo
    Mongioj, Valeria
    Carrara, Mauro
    Palazzi, Mauro
    Franceschini, Marzia
    Bergamini, Cristiana
    Locati, Laura
    Iannacone, Eva
    Guzzo, Marco
    Ibba, Tullio
    Crippa, Flavio
    Licitra, Lisa
    Pignoli, Emanuele
    Fallai, Carlo
    [J]. FUTURE ONCOLOGY, 2013, 9 (01) : 103 - 114
  • [27] Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma
    Aftab, Omer
    Liao, Shufang
    Zhang, Rongjun
    Tang, Nan
    Luo, Meiqing
    Zhang, Bin
    Shahi, Sanjeev
    Rai, Raju
    Ali, Jazib
    Jiang, Wei
    [J]. RADIATION ONCOLOGY, 2020, 15 (01)
  • [28] Addition of chemotherapy to intensity-modulated radiotherapy does not improve survival in stage II nasopharyngeal carcinoma patients
    Wang Fangzheng
    Jiang Chuner
    Sun Quanquan
    Ye Zhimin
    Liu Tongxin
    Liu Jiping
    Sakamoto, Masoto
    Wu Peng
    Shi Kaiyuan
    Qin Weifeng
    Fu Zhenfu
    Jiang Yangming
    [J]. JOURNAL OF CANCER, 2018, 9 (11): : 2030 - 2037
  • [29] Intensity-modulated radiotherapy versus conventional three-dimensional conformal radiotherapy for boost or salvage treatment of nasopharyngeal carcinoma
    Hsiung, CY
    Yorke, ED
    Chui, CS
    Hunt, MA
    Ling, CC
    Huang, EY
    Wang, CJ
    Chen, HC
    Yeh, SA
    Hsu, HC
    Amols, HI
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 53 (03): : 638 - 647
  • [30] Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma
    Xia, P
    Fu, KK
    Wong, GW
    Akazawa, C
    Verhey, LJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (02): : 329 - 337